Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Belo Horizonte; s.n; 2009. 152 p. tab.
Thesis in Portuguese | LILACS, BBO | ID: lil-557492

ABSTRACT

Estudos sobre crescimento gengival (CG) e fatores de risco a ele relacionados em transplantados renais sob o uso dos imunossupressores ciclosporina A (CsA) e tacrolimus (Tcr) têm mostrado resultados diversos e não foram encontrados relatos sobre avaliações com sirolimus (Sir). Assim, o presente estudo, apresentado na forma de uma revisão de literatura e três artigos científicos, teve as seguintes propostas de investigação: 1) avaliar a prevalência, gravidade e variáveis de risco associadas ao CG nos regimes de imunossupressão baseados em Sir; 2) avaliar o polimorfismo do gene da interleucina-6 (IL-6) em indivíduos medicados com CsA, Tcr e Sir e sua associação com o CG; 3) avaliar a frequencia micorbiana e variáveis de risco para o CG nos regimes de imunissupressão baseados em CsA, Tcr e Sir. Uma amostra elegível foi seleciona em dois hospitais públicos de Belo Horizonte, Brasil. Participaram do estudo transplantados renais de ambos os gêneros, faixa etária variada, grupo racial heterogêneo, com no mínimo 6 dos 12 dentes anteriores. Os dados periodontais incluíram avaliação visual do CG, índice de placa e índice de sangramento papilar...


Subject(s)
Humans , Male , Female , Cyclosporine/therapeutic use , Gingival Overgrowth/complications , Immunosuppression Therapy/trends , Sirolimus/therapeutic use , Tacrolimus/therapeutic use , Kidney Transplantation/adverse effects , Risk Factors
2.
Rev. invest. clín ; 57(2): 237-243, mar.-abr. 2005.
Article in Spanish | LILACS | ID: lil-632476

ABSTRACT

The history of Immunosuppresslon is a long one. From the utilization of steroids and azathloptlne In the 50's to the design of humanized molecules that specifically block cell surface receptors. Liver transplantation is one of the procedures that benefit the most with the development of new immunosuppressors and is also one of the reasons to create a new branch in research and clinical practice: transplant medicine. It also set the standards for research in the "immunologic tolerance" field. The cornerstone in the post-liver transplant stage is the utilization of calcineurin inhibitors combined with new anti-metabolites and monoclonal antibodies. All these settings conforms a promising field in the research of new and better immunosuppressing agents.


Se ha recorrido mucho camino desde el diseño de la inmunosupresión en la década de los 50's. Desde la utilización de los esteroides y la azatioprina hasta el desarrollo de moléculas humanizadas, que bloquean específicamente receptores de superficie celular para inducir tolerancia del injerto, ha transcurrido medio siglo. El trasplante hepático ha sido uno de los procedimientos más beneficiados con el desarrollo de las nuevas drogas inmunosupresoras y ha dado origen a una nueva rama de la medicina: la medicina de trasplantes. También ha sentado las bases de investigación tendiente a lograr la "tolerancia inmunológica" del órgano trasplantado. La piedra angular en la inmunosupresión postrasplante hepático es la utilización de los inhibidores de calcineurina que, en combinación con nuevos antimetabolitos y anticuerpos monoclonales, dibujan un futuro promisorio en la búsqueda de mejores agentes.


Subject(s)
Humans , Immunosuppression Therapy/trends , Immunosuppressive Agents/therapeutic use , Liver Transplantation/immunology , Antibodies, Monoclonal/therapeutic use , Antimetabolites/therapeutic use , Azathioprine/therapeutic use , Calcineurin/antagonists & inhibitors , Cyclosporine/therapeutic use , Forecasting , Graft Rejection/prevention & control , Immunosuppression Therapy/methods , Immunosuppressive Agents/classification , Methylprednisolone/therapeutic use , /antagonists & inhibitors , /immunology , Treatment Outcome , Tacrolimus/therapeutic use
4.
Medicina (B.Aires) ; 60(1): 67-80, 2000.
Article in Spanish | LILACS, BINACIS | ID: biblio-1165073

ABSTRACT

Immunosuppressive drugs make possible the acceptance of organ allografts among individuals with differences in Major Histocompatibility Antigens (HLA). Transplantation of vital organs prolongs the survival of patients with terminal diseases, and this procedure has become a routine practice in the clinic, mainly because of advances in immunosuppressive therapy. Some immunosuppressive drugs, such as glucocorticosteroids and azathioprine, have been used for the past 30 years. More recently, newly discovered agents with a better ratio of efficacy to toxicity have been added to the armamentarium of anti-rejection therapies. Progress in understanding T cell activation in response to alloantigens has contributed to the development of new and more selective strategies to control the immune response and prevent acute rejection. The use of drugs in combination, with or without monoclonal antibodies, has also improved the efficacy and reduced the toxicity of immunosuppressive therapies. The new agents include drugs that interfere with calcineurin, inhibitors of de novo purine biosynthesis, kinase inhibitors, as well as monoclonal antibodies that block activation signals on the surface of T cells or co-stimulatory signals between T cells and antigen-presenting cells. In this review the modes of action of commonly used immunosuppressive drugs are described. Successful new strategies are also being developed to establish tolerance to allografts in rodents and non-human primates. The progress in these approaches, although still in the experimental stages, offers promising alternatives for these patients in the future. Treatment protocols using combinations of drugs with antibodies that might produce tolerance in humans are also discussed.


Subject(s)
Humans , Immunosuppression Therapy/trends , Immune Tolerance , Immunosuppressive Agents/pharmacology , Transplantation, Homologous , Transplantation Immunology , Lymphocyte Activation , T-Lymphocytes/immunology , Organ Transplantation
5.
Rev. SOCERJ ; 11(3): 216-8, jul.-set. 1998. ilus
Article in Portuguese | LILACS | ID: lil-281845

ABSTRACT

O transplante cardíaco evoluiu como modalidade de tratamento para a insuficiência cardíaca terminal, que apresenta elevada mortalidade apesar do tratamento farmacológico atual. O surgimento da ciclosporina na década de 80 possibilitou a realizaçäo de milhares de transplantes com sobrevida maior que 80 'por cento' no primeiro ano. No Rio de Janeiro foi criado, em 1994, o Gaveatransplante, na tentativa de preencher uma lacuna existente na atividade transplantadora cardíaca na cidade. Foram realizados até o momento três transplantes cardíacos. O programa conta com uma equipe multidisciplinar na assistência aos pacientes candidatos e no seguimento a longo prazo dos transplantados. Os cuidados com a imunossupressäo e a biópsias endomiocárdicas seriadas säo os alicerces para a sustentaçäo do transplantado.


Subject(s)
Humans , Immunosuppression Therapy/trends , Immunosuppression Therapy , Heart Failure/surgery , Heart Failure/mortality , Heart Failure/therapy , Heart Transplantation/trends , Heart Transplantation , Brazil , Cyclosporine/therapeutic use , Postoperative Complications , Drug Prescriptions , Time Factors
7.
Antibiot. infecc ; 1(1): 30-7, sept. 1992. ilus, tab
Article in Spanish | LILACS | ID: lil-133027

ABSTRACT

En las últimas décadas y debido al uso de potentes antibióticos de amplio espectro, el empleo de técnica invasivas, tanto diagnósticas como terapéuticas y la mayor sobrevida de pacientes inmunosuprimidos han traido como consecuencia un incremento significativo en la frecuencia de infecciones micóticas sistémicas, que como microorganismos oportunistas, representan una importante causa de morbi-mortalidad en pacientes críticammente enfermos. Esta revisión tiene el objetivo de hacer énfasis en los principales aspectos tanto etiológicos, diagnósticos, terapéuticos y especialmente preventivos, que sirvan de guía práctica para el manejo de esta preocupante patología


Subject(s)
Humans , Cross Infection , Immunosuppression Therapy/trends , Mycoses/etiology , Mycoses/mortality , Mycoses/prevention & control , Opportunistic Infections/mortality
SELECTION OF CITATIONS
SEARCH DETAIL